Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism
- Conditions
- Reactive Hypoglycemia
- Interventions
- Drug: Placebo
- Registration Number
- NCT00847080
- Lead Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Brief Summary
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.
- Detailed Description
Symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion. Patients with this abnormality as an early manifestation of glucose intolerance are at higher risk of type 2 diabetes. The pathophysiology of this abnormality appears to be related with delayed first phase insulin release. Improvement of first phase insulin secretion and delay in gastric emptying induced by sitagliptin phosphate could have favorable effects in patients in whom delayed insulin secretion is associated with reactive hypoglycemia.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Clinical and biochemical diagnosis of prediabetic reactive hypoglycemia
- Must be able to swallow tablet
- Negative pregnancy test (when appropriate)
- Renal insufficiency
- Hepatic insufficiency
- Diabetes (any type)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sitagliptin Sitagliptin phosphate - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Clinical improvement assessed by a validated questionnaire 2 weeks
- Secondary Outcome Measures
Name Time Method Glucose, insulin, GLP1, GIP First and last evaluations
Trial Locations
- Locations (1)
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
🇲🇽Mexico, DF, Mexico